Verrica Pharmaceuticals (VRCA) Interest Expenses (2017 - 2026)

Verrica Pharmaceuticals' Interest Expenses history runs 10 years deep, the most recent figure standing at $1.0 million for Q1 2026.

• In Q1 2026, Interest Expenses fell 53.2% year-over-year to $1.0 million; the TTM figure through Mar 2026 stood at $1.0 million (down 87.33% YoY), while the FY2025 annual figure was $73.7 million, up 4.02% from the prior year.
• Interest Expenses for Q1 2026 stood at $1.0 million, down from $3.4 million in the prior quarter.
• The five-year high for Interest Expenses was $2.7 billion in Q1 2024, with the low at $100000.0 in Q3 2022.
• The 5-year median for Interest Expenses is $2.0 million (2023), against an average of $170.6 million.
• The sharpest annual moves came in 2024 and 2025: Interest Expenses soared 62433.23% in 2024, then plunged 99.92% in 2025.
• Verrica Pharmaceuticals' Interest Expenses stood at $384000.0 in 2022, then jumped by 377.34% to $1.8 million in 2023, then retreated by 5.46% to $1.7 million in 2024, then jumped by 95.56% to $3.4 million in 2025, then tumbled by 69.58% to $1.0 million in 2026.
• Business Quant data shows VRCA's Interest Expenses at $1.0 million in Q1 2026, $3.4 million in Q4 2025, and $5.9 million in Q3 2025.